Concise, sourced briefs on the developments most likely to affect how you practice — outbreaks, approvals, guideline shifts — each linking to a full TheraCALC reference.
Bictegravir/lenacapavir adds a two-drug, once-daily single-tablet switch option for adults already virologically suppressed on stable ART. The practical story is simplification, not first-line replacement: Days 1 and 2 require supplemental oral Sunlenca before Bixlenvo-only maintenance.
Merck's once-daily pill lowered LDL by ~56–59% vs placebo in two late-stage trials, holding up in familial hypercholesterolemia. The breakthrough is the route: PCSK9 lowering without an injection — an access and adherence shift for statin-inadequate patients. Open question: cardiovascular-outcomes data vs the LDL surrogate.
6,707 lab-confirmed across 45 states (>11,500 under review) — a 9-state outbreak (IL, IN, KS, KY, MI, OH, OK, PA, WV) linked to shredded iceberg lettuce served at some Taco Bell locations. TMP–SMX remains the drug of choice — the brief covers recognition, host-stratified dosing, monitoring, and the stool-O&P testing trap that misses the diagnosis.